Molecularly targeted therapy in renal cell carcinoma: Where do we go from here?

Expert Review of Anticancer Therapy

Volumn 6, Issue 12, 2006, Pages 1753-1760

  Rini, Brian I ^a  

^a TAUSSIG CANCER INSTITUTE   (United States)

Author keywords

Bevacizumab; CAIX; COX 2; Cytokines; Renal carcinoma; Sorafenib; Sunitinib; Temsirolimus; VEGF

Indexed keywords

ALPHA INTERFERON; BEVACIZUMAB; CARBONATE DEHYDRATASE IX; CELECOXIB; CYCLOOXYGENASE 2; CYTOKINE; ERLOTINIB; INTERFERON; INTERLEUKIN 2; PLACEBO; PLATELET DERIVED GROWTH FACTOR; SORAFENIB; SUNITINIB; TEMSIROLIMUS; VASCULOTROPIN; VON HIPPEL LINDAU PROTEIN;

ADVANCED CANCER; ASTHENIA; CANCER IMMUNOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CLEAR CELL CARCINOMA; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CYTOREDUCTIVE SURGERY; DIARRHEA; DISEASE FREE SURVIVAL; DRUG ERUPTION; DRUG MECHANISM; DRUG MEGADOSE; DRUG RESPONSE; DRUG TARGETING; DRUG TOLERABILITY; FATIGUE; GENE INACTIVATION; HAND FOOT SYNDROME; HUMAN; HYPERTENSION; KIDNEY CARCINOMA; LOW DRUG DOSE; META ANALYSIS; METASTASIS; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NEPHRECTOMY; OVERALL SURVIVAL; PATIENT SELECTION; PHENOTYPE; PROTEIN EXPRESSION; PROTEINURIA; REVIEW; SKIN MANIFESTATION; STOMATITIS; SYSTEMATIC REVIEW; SYSTEMIC THERAPY; TUMOR VOLUME;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BENZENESULFONATES; CARCINOMA, RENAL CELL; CASE MANAGEMENT; CLINICAL TRIALS; COMBINED MODALITY THERAPY; CYTOKINES; HUMANS; INDOLES; KIDNEY NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; NEPHRECTOMY; PYRIDINES; PYRROLES; SIROLIMUS; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 33846051511     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/14737140.6.12.1753     Document Type: Review

References (38)

1. Escudier B, Szczylik C, Eisen T et al. Randomized Phase III trial of the Raf kinase and VEGFZ inhibitor sorafenib (BAY 43-9006) in patients with advanced renal cell carcinoma (RCC). Proc. Am. Soc. Clin. Oncol. 23 (16S), 4510 (2005).
2. Motzer RJ, Rini BI, Bukowski RM et al. Sunitinib in patients with metastatic renal cell carcinoma. JAMA 295 (21), 2516-2524 (2006).
3. Motzer RJ, Hutson TE, Tomczak P et al. Phase III randomized trial of sunitinib malate (SU11248) versus interferon-α (IFN-α) as first-line systemic therapy for patients with metastatic renal cell carcinoma (mRCC). J. Clin. Oncol. 24, S2 (2006) (Abstract LBA3).
4. Yang JC, Haworth L, Sherry RM et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N. Engl. J. Med. 349(5), 427-434 (2003).
5. Bukowski RM, Kabbinavar F, Figlin RA et al. Bevacizumab with or without erlotinib in metastatic renal cell carcinoma (RCC). J. Clin. Oncol. 24, S222 (2006) (Abstract 4523).
6. Hudes G, Carducci M, Tomczak P et al. A Phase 3, randomized, 3-arm study of temsirolimus (TEMSR) or interferon-α (IFN) or the combination of TEMSR + IFN in the treatment of first-line, poor-risk patients with advanced renal cell carcinoma (adv RCC). J. Clin. Oncol. 24, S2 (2006) (Abstract LBA4).
7. Mcdermott DF, Regan MM, Clark JI et al. Randomized Phase III trial of high-dose interieukin-2 versus subcutaneous interieukin-2 and interferon in patients with metastatic renal cell carcinoma. J. Clin. Oncol. 23(1), 133-141 (2005).
8. Yang JC, Sherry RM, Steinberg SM et al. Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer. J. Clin. Oncol. 21(16), 3127-3132 (2003).
9. Interferon-α and survival in metastatic renal carcinoma: early results of a randomised controlled trial. Medical Research Council Renal Cancer Collaborators. Lancet 353(9146), 14-17 (1999).
10. Pyrhonen S, Salminen E, Ruutu M et al. Prospective randomized trial of interferon α-2a plus vinblastine versus vinblastine alone in patients with advanced renal cell cancer. J. Clin. Oncol. 17(9), 2859-2867 (1999).
11. Coppin C, Porzsolt F, Awa A et al. Immunotherapy for advanced renal cell cancer. Cochrane Databave Syst. Rev. (1), CDO01425 (2005).
12. Shuin T, Kondo K, Torigoe S et al. Frequent somatic mutations and loss of heterozygosity of the von Hippel-Lindau tumor suppressor gene in primary human renal cell carcinomas. Cancer-Res. 54(11), 2852-2855 (1994).
13. Herman JG, Latif F, Weng Y et al. Silencing of the VHL tumor-suppressor gene by DNA methylation in renal carcinoma. Proc. Natl Acad. Sci. USA 91(21), 9700-9704 (1994).
14. Presta LG, Chen H, O'Connor SJ et al. Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res. 57 (20), 4593-4599 (1997).
15. Rini BI, Halabi S, Taylor J, Small EJ, Schilsky RL. Cancer and Leukemia Group B 90206: a randomized Phase III trial of interferon-α or interferon-α plus antivascular endothelial growth factor antibody (bevacizumab) in metastatic renal cell carcinoma. Clin. Cancer Res. 10(8), 2584-2586 (2004).
16. Sun L, Liang C, Shirazian S et al. Discovery of 5-[5-fluoro-2-oxo-1,2- dihydroindol-(3Z)-ylidenemethyl]-2,-4- dimethyl-1Hpyrrole-3-carboxylic acid (2-diethylaminoethyl)amide, a novel tyrosine kinase inhibitor targeting vascular endothelial and platelet-derived growth factor receptor tyrosine kinase. J. Med. Chem. 46(7), 1116-1119 (2003).
17. Mendel DB, Laird AD, Xin X et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin. Cancer Res. 9(1), 327-337 (2003).
18. Motzer RJ, Michaelson MD, Redman BG et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J. Clin. Oncol. 24(1), 16-24 (2006).
19. Motzer RJ, Rini BI, Bukowski RM et al. Sunitinib in patients with metastatic renal carcinoma. JAMA 295(21), 2516-2524 (2006).
20. Ratain MJ, Eisen T, Stadler WM et al. Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J. Clin. Oncol. 24(16), 2505-2512 (2006).
21. Atkins MB, Hidalgo M, Stadler WM et al. Randomized Phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. J. Clin. Oncol. 22(5), 909-918 (2004).
22. Motzer RJ, Bacik J, Murphy BA, Russo P, Mazumdar M. Interferon-α as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J. Clin. Oncol. 20(1), 289-296 (2002).
23. Mekhail TM, Abou-Jawde RM, Boumerhi G et al. Validation and extension of the Memorial Sloan-Kettering prognostic factors model for survival in patients with previously untreated metastatic renal cell carcinoma. J. Clin. Oncol. 23(4), 832-841 (2005).
24. Grabmaier K, A de Weijert MC, Verhaegh GW, Schalken JA, Oosterwijk E. Strict regulation of CAIX(G250/MN) by HIF-1α, in clear cell renal cell carcinoma. Oncogene 23(33), 5624-5631 (2004).
25. Bui MH, Seligson D, Han KR et al. Carbonic anhydrase IX is an independent predictor of survival in advanced renal clear cell carcinoma: implications for prognosis and therapy. Clin. Cancer Res. 9(2), 802-811 (2003).
26. Atkins M, Regan M, McDermott D et al. Carbonic anhydrase IX expression predicts outcome of interleukin 2 therapy for renal cancer. Clin. Cancer Res. 11(10), 3714-3721 (2005).
27. Rini BI, Weinberg V, Dunlap S et al. Maximal COX-2 immunostaining and clinical response to celecoxib and interferon a therapy in metastatic renal cell carcinoma. Cancer 106(3), 566-575 (2006).
28. Gollob Richmond T, Jones JL et al. Phase II trial of sorafenib plus interferon-α 2b (IFN-(α2b) as first- or second-line therapy in patients with metastatic renal cell cancer. Proc. Am. Soc. Clin. Oncol. 24, 226S (2006).
29. Ryan CW, Goldman BH, Lara J, Beer TM, Drabkin HA, Crawford ED. Sorafenib plus interferon-α2b (IFN) as first-line therapy for advanced renal cell carcinoma (RCC): SWOC 0412. Proc. Am. Soc. Clin. Oncol. 24, 223S (2006).
30. Flanigan RC, Salmon SE, Blumenstein BA et al. Nephrectomy followed by interferon (x-2b compared with interferon β-2b alone for metastatic renal-cell cancer. N. Engl. J. Med. 345(23), 1655-1659 (2001).
31. Mickisch GH, Garin A, van Poppel H, de Prijck L, Sylvester R. Radical nephrectomy plus interferon-α-based immunotherapy compared with interferon α alone in metastatic renal-cell carcinoma: a randomised trial. Lancet 358(9286), 966-970 (2001).
32. Flanigan RC, Mickisch G, Sylvester R et al. Cytoreductive nephrectomy in patients with metastatic renal cancer: a combined analysis. J. Urol. 171(3), 1071-1076 2004.
33. Gatenby RA, Gawlinski ET, Tangen CM, Flanigan RC, Crawford ED. The possible role of postoperative azotemia in enhanced survival of patients with metastatic renal cancer after cytoreductive nephrectomy. Cancer Res. 62(18), 5218-5222 (2002).
34. + T-cell reactivity to the receptor tyrosine kinase EphA2 in patients with renal cell carcinoma. Cancer Res. 63(15), 4481-4489 (2003).
35. + patients with renal cell carcinoma or melanoma. J. Exp. Med. 196(5), 619-628 (2002).
36. Rini BI, George DI, Michaelson MD et al. Efficacy and safety off surdtinib malate in bevacizumab-refractory metastatic renal cell carcinoma. Proc. Am. Soc. Clin. Oncol. 24, S222 (2006).
37. Tamaskar I, Shaheen P, Wood L et al. Antitumor effects of sorafenib and sunitinib in patiens (pts) with metastatic renal cell carcinoma (mRCC) who had prior therapy with anti-angiogenic agents. Proc. Am. Soc. Oncol. 24,S18 (2006).
38. Grothey A, Sargent D, Goldberg RM, Schmoll HJ. Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment. J. Clin. Oncol. 22(7), 1209-1214 (2004).